Clinical Trials Directory

Trials / Completed

CompletedNCT01178905

Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants

Clinical Evaluation of a Gentle But Safe Ultrashort-term Heat Inactivation Procedure of Raw Breast Milk (BM) Containing Virulent Cytomegalovirus for Preventing CMV-infection of Preterm Infants

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
Sponsor
University Hospital Tuebingen · Academic / Other
Sex
All
Age
23 Weeks – 40 Weeks
Healthy volunteers

Summary

To evaluate, in a prospective multicenter study, ultrashort-term heat inactivation for the prevention of Cytomegalovirus (CMV) transmission in preterm infants (\<32 weeks gestational age or \<1500 g birth weight) under clinical conditions. Inactivation will be done only during the period of infectivity of breast milk, characterized by viral excretion strongly associated with subsequent infection, monitored by periodic virologic examinations of BM and urine of the infant. Thus the investigators hypothesis is that no CMV transmission through breast milk will occur using a gentle ultrashort heat inactivation procedure applied to infective breast milk. The protocol has been approved by the ethics committee of Tuebingen University Hospital.

Conditions

Interventions

TypeNameDescription
PROCEDUREultrashort heat inactivation

Timeline

Start date
2010-08-01
Primary completion
2012-10-01
First posted
2010-08-10
Last updated
2013-04-24

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01178905. Inclusion in this directory is not an endorsement.